Core Viewpoint - The announcement of a strategic cooperation agreement between New World (301277) and Nanjing Zhihe Pharmaceutical Technology Co., Ltd. focuses on the development and commercialization of GLP-1 long-acting peptide innovative drugs, which is seen as a significant step for the company's innovation business development [1]. Group 1: Partnership Details - New World and Zhihe Pharmaceutical will collaborate on the research, production, commercialization, and external transactions of target molecules and products in the GLP-1 long-acting peptide innovative drug field [1]. - The agreement includes a profit-sharing model based on product revenue and net sales [1]. - A joint committee will be established to manage all activities related to the cooperation project [1]. Group 2: Strategic Importance - The signing of the agreement is considered an important measure for the company's long-term development and is expected to have a positive impact [1]. - The collaboration aims to leverage the resources and strengths of both companies to develop GLP-1 long-acting peptide innovative drugs, providing better options for patients with metabolic diseases [1].
新天地与知和医药签署合作开发及许可协议